Nevertheless, the combination of CDK9 inhibitors with either Bortezomib, Doxorubicin or Venetoclax seems to overcome resistance to therapy and cause increased apoptosis of MM cells. The gene discussed is CDK9; the disease is Miyoshi myopathy.